New Zealand - English - Medsafe (Medicines Safety Authority)

orion pharma (nz) limited - carbidopa monohydrate 54.1mg equivalent to 50 mg carbidopa; entacapone 200mg; levodopa 200mg - film coated tablet - 200mg/50mg/200mg - active: carbidopa monohydrate 54.1mg equivalent to 50 mg carbidopa entacapone 200mg levodopa 200mg excipient: croscarmellose sodium ethanol glycerol hypromellose iron oxide red magnesium stearate   maize starch mannitol polysorbate 80 povidone purified water   sucrose titanium dioxide - latest regulatory activity

New Zealand - English - Medsafe (Medicines Safety Authority)

orion pharma (nz) limited - carbidopa monohydrate 13.5mg equivalent to carbidopa 12.5 mg; entacapone 200mg; levodopa 50mg - film coated tablet - 50mg/12.5mg/200mg - active: carbidopa monohydrate 13.5mg equivalent to carbidopa 12.5 mg entacapone 200mg levodopa 50mg excipient: croscarmellose sodium ethanol glycerol hypromellose iron oxide red iron oxide yellow magnesium stearate maize starch mannitol polysorbate 80 povidone purified water sucrose titanium dioxide - the treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

New Zealand - English - Medsafe (Medicines Safety Authority)

orion pharma (nz) limited - carbidopa monohydrate 20.25mg equivalent to 18.75 mg carbidopa; entacapone 200mg; levodopa 75mg - film coated tablet - 75mg/18.75mg/200mg - active: carbidopa monohydrate 20.25mg equivalent to 18.75 mg carbidopa entacapone 200mg levodopa 75mg excipient: croscarmellose sodium ethanol glycerol hypromellose iron oxide red magnesium stearate   maize starch mannitol polysorbate 80 povidone purified water sucrose titanium dioxide - stalevo is indicated for the treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

New Zealand - English - Medsafe (Medicines Safety Authority)

inova pharmaceuticals (new zealand) limited - tolcapone 100mg - film coated tablet - 100 mg - active: tolcapone 100mg excipient: calcium hydrogen phosphate ethylcellulose hypromellose iron oxide yellow lactose monohydrate magnesium stearate microcrystalline cellulose povidone purified talc   sodium laurilsulfate sodium starch glycolate titanium dioxide triacetin - tasmar is indicated for use in combination with levodopa/benserazide and levodopa/carbidopa in parkinson's disease, including both fluctuating and non-fluctuating patients.

Israel - English - Ministry of Health

inovamed pharma ltd, israel - carbidopa; entacapone; levodopa - film coated tablets - levodopa 100 mg; carbidopa 25 mg; entacapone 200 mg - levodopa - levodopa - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

Israel - English - Ministry of Health

inovamed pharma ltd, israel - carbidopa as monohydrate; entacapone; levodopa - film coated tablets - carbidopa as monohydrate 18.75 mg; entacapone 200 mg; levodopa 75 mg - levodopa - levodopa - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa/decarboxylase (ddc) inhibitor treatment.

Israel - English - Ministry of Health

inovamed pharma ltd, israel - carbidopa as monohydrate; entacapone; levodopa - film coated tablets - levodopa 125 mg; entacapone 200 mg; carbidopa as monohydrate 31.25 mg - levodopa - levodopa - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa/decarboxylase (ddc) inhibitor treatment.

Israel - English - Ministry of Health

inovamed pharma ltd, israel - carbidopa; entacapone; levodopa - film coated tablets - levodopa 50 mg; carbidopa 12.5 mg; entacapone 200 mg - levodopa and decarboxylase inhibitor - levodopa and decarboxylase inhibitor - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

Israel - English - Ministry of Health

inovamed pharma ltd, israel - carbidopa; entacapone; levodopa - film coated tablets - levodopa 150 mg; carbidopa 37.5 mg; entacapone 200 mg - levodopa and decarboxylase inhibitor - levodopa and decarboxylase inhibitor - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

Israel - English - Ministry of Health

novartis israel ltd - entacapone - film coated tablets - entacapone 200 mg - entacapone - entacapone - entacapone is indicated as an adjunct to standard preparations of levodopa/benserazide or levodopa/carbidopa for use in patients with parkinson`s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.